Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) had its price objective upped by investment analysts at Wells Fargo & Company from $95.00 to $110.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential downside of 4.59% from the company’s previous close.
HALO has been the topic of a number of other reports. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a research note on Friday, October 16th. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. TD Cowen lifted their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.00.
Read Our Latest Research Report on Halozyme Therapeutics
Halozyme Therapeutics Stock Performance
NASDAQ:HALO opened at $115.29 on Friday. Halozyme Therapeutics has a 1 year low of $61.22 and a 1 year high of $134.00. The firm’s fifty day simple moving average is $115.26 and its 200 day simple moving average is $84.57. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm has a market capitalization of $13.09 billion, a PE ratio of 34.55, a PEG ratio of 0.49 and a beta of 0.92.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same quarter in the previous year, the business earned $1.72 EPS. The business’s revenue was up 39.1% on a year-over-year basis. On average, sell-side analysts anticipate that Halozyme Therapeutics will post 8.32 EPS for the current year.
Insider Transactions at Halozyme Therapeutics
In other news, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Halozyme Therapeutics
Large investors have recently added to or reduced their stakes in the company. Horizon Investment Services LLC acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $2,254,000. WINTON GROUP Ltd raised its stake in shares of Halozyme Therapeutics by 704.6% in the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after purchasing an additional 52,848 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at $1,025,000. Great Lakes Advisors LLC bought a new position in Halozyme Therapeutics in the second quarter worth $2,821,000. Finally, Chase Investment Counsel Corp bought a new position in Halozyme Therapeutics in the second quarter worth $2,035,000. Institutional investors and hedge funds own 97.79% of the company’s stock.
Halozyme Therapeutics News Roundup
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Revenue rose 39% year over year to a record $493 million, while royalty revenue climbed 44% to $341 million. Adjusted diluted EPS of $2.39 also topped analyst expectations of about $2.30. Halozyme Q3 results and guidance
- Positive Sentiment: Halozyme raised its 2026 guidance, projecting revenue of $1.86 billion–$1.925 billion, royalty revenue of $1.235 billion–$1.255 billion, adjusted EBITDA of $1.24 billion–$1.29 billion, and non-GAAP EPS of $8.75–$9.05. Higher guidance points to stronger expected growth and earnings. Halozyme Q3 results and guidance
- Positive Sentiment: The company expanded ENHANZE collaboration agreements with three existing partners, and three ENHANZE programs advanced into Phase 1 clinical development, adding to potential future royalty opportunities. Halozyme Q3 results and guidance
- Negative Sentiment: Despite the earnings beat and raised outlook, reports said HALO shares fell after the results. The supplied coverage does not identify a specific reason; the reaction may reflect investor expectations or profit-taking rather than weakness in the reported quarter. Halozyme Q3 stock reaction
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.
Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
